Friday, February 1, 2019 @ 12:00 am
Santersus SA (Switzerland), a privately held innovative selective plasmapheresis start-up company, announces that the Company has strengthened its senior leadership team with the appointment of Dr Andrew Daniel Aswani to the newly created position of Medical Director.
“We are very pleased to welcome Dr. Aswani to our senior management team as he brings relevant experience and significant expertise in areas key to Santersus,” stated Dr. Dmitry D. Genkin, co-founder of Santersus SA.
Dr Andrew Daniel Aswani
MD, PhD (London), MRCP (London), FRCA (UK), EDIC, FFICM.
Dr Aswani is a consultant in Intensive Care Medicine & Anaesthesia at Guy’s and St Thomas’ NHS Foundation Trust, London. He is also Consultant in Intensive Care Medicine at London Bridge Hospital (HCA). Dr Aswani has been dedicated to a top tier career in Intensive Care Medicine and Anaesthesia since 2001. Dr Aswani is the Clinical Lead for Junior Doctors and the Clinical Lead for Vascular Access at Guy’s and St Thomas’. He is Scientific Advisory Board member of Cannaray Ltd.
Dr Aswani undertook extensive training in multiple specialties in the leading clinical institutions in Manchester, Sydney and London. He completed his PhD thesis at Queen Mary University of London (2010-2016) where he studied the role of cell-free circulating DNA released into the circulation in shock states to explain sterile organ injury and death.